Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma

IF 4.7 2区医学 Q1 ONCOLOGY

Current Oncology Reports Pub Date : 2024-04-11 DOI:10.1007/s11912-024-01523-8

Michael A. Liu, Jennifer W. Li, Karie Runcie

{"title":"Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma","authors":"Michael A. Liu, Jennifer W. Li, Karie Runcie","doi":"10.1007/s11912-024-01523-8","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>To summarize and evaluate the literature on treatment approaches for oligometastatic and locally recurrent urothelial cancer.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>There is no clear definition for oligometastatic urothelial cancers due to limited data. Studies focusing on oligometastatic and locally recurrent urothelial cancer have been primarily retrospective. Treatment options include local therapy with surgery or radiation, and generalized systemic therapy such as chemotherapy or immunotherapy.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Oligometastatic and locally recurrent urothelial cancers remain challenging to manage, and treatment requires an interdisciplinary approach. Systemic therapy is nearly always a component of current care in the form of chemotherapy, but the role of immunotherapy has not been explored. Consideration of surgical and radiation options may improve outcomes, and no studies have compared directly between the two localized treatment options. The development of new prognostic and predictive biomarkers may also enhance the treatment landscape in the future.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":"165 1","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-024-01523-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of Review

To summarize and evaluate the literature on treatment approaches for oligometastatic and locally recurrent urothelial cancer.

Recent Findings

There is no clear definition for oligometastatic urothelial cancers due to limited data. Studies focusing on oligometastatic and locally recurrent urothelial cancer have been primarily retrospective. Treatment options include local therapy with surgery or radiation, and generalized systemic therapy such as chemotherapy or immunotherapy.

Summary

Oligometastatic and locally recurrent urothelial cancers remain challenging to manage, and treatment requires an interdisciplinary approach. Systemic therapy is nearly always a component of current care in the form of chemotherapy, but the role of immunotherapy has not been explored. Consideration of surgical and radiation options may improve outcomes, and no studies have compared directly between the two localized treatment options. The development of new prognostic and predictive biomarkers may also enhance the treatment landscape in the future.

Abstract Image

查看原文本刊更多论文

寡转移性和局部复发性尿路上皮癌的治疗方法

最新研究结果由于数据有限，对少转移性尿路上皮癌还没有明确的定义。针对少转移性和局部复发性尿路癌的研究主要是回顾性的。治疗方案包括手术或放疗等局部治疗，以及化疗或免疫疗法等全身治疗。摘要寡转移和局部复发性尿路癌的治疗仍然具有挑战性，治疗需要跨学科的方法。系统治疗几乎总是以化疗的形式作为当前治疗的一部分，但免疫疗法的作用尚未得到探讨。考虑手术和放射治疗方案可能会改善治疗效果，但目前还没有研究对这两种局部治疗方案进行直接比较。新的预后和预测生物标志物的开发也可能会改善未来的治疗前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.